ARCHIVES

Tyrosine Kinase Inhibitor Encoraging For NSCLC

This article is from The Cancer Letter archive.

Vol. 24 No. 7 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

House subcommittee’s 5.6% Increase For NIH includes $2.5 Billion for NCI

July 18, 1997

Nexavar Improves PFS In HER-2 Negative Breast Cancer

May 27, 2011

Schmidt Already Working For NIH Despite His Opposition To Kennedy’s New Research Panel

April 5, 1974

Non-Caucasians At Higher Risk For Severe Breast Cancer Pain

December 28, 2007

New Frederick RFP Out May 14; Five contracts To Be Awarded, Each For Five to Seven Years

May 2, 1986

NCI-Approved CTEP Trials For the Month of September

September 28, 2012